Intraperitoneal injection of the plant-growth retardant, Phosfon, significantly stimulates the incorporation in vivo of radioactive acetate into cholesterol in several organs of the mature male rat. Amo 1618, another plant-growth retardant, does not produce this response. The Phosfon effect is not observed with weanlings, nor when the cholesterol precursors glucose and mevalonate are administered.
INTRODUCTION
Several articles (Pa1eg and Seamark 1968; Paleg 1970a Paleg , 1970b  Paleg and Sabine 1971) have demonstrated that a group of chemically diverse compounds, collectively called plant-growth retardants, have the capacity not only to influence plant growth but also to inhibit mammalian cholesterol biosynthesis as measured in cell-free systems of rat liver. Some members of the group contain quaternary nitrogen configurations and in this regard are similar to more well-known inhibitors of steroid biosynthesis such as certain SK & F compounds. Some retardants have phosphonium ions or other types of active sites. In common with the SK & F compounds (Holmes and Di Tullio 1962) , the retardants have been shown to act at at least two points in the biosynthetic sequence leading to cholesterol, one before and one after the formation of mevalonate (Paleg 1970b) . Recent results (Pa1eg and Sabine 1971; Douglas and Paleg 1972) with various types of tissues indicated that the retardants can also inhibit sterol biosynthesis by intact cells, and this suggested that an examination of the effects of these compounds in vivo would be desirable. The relevance of this work is strongly underlined by the fact that plant-growth retardants have important agricultural effects, and commercial uses are becoming more widespread.
II. MATERIALS AND METHODS

(a) Animals and Diets
Male, hooded Wistar rats, both weanlings (16-18 days, approx. 30 g) and young adults (3-4 months, approx. 250-300 g), as supplied from this University's Central Animal House, were used in these studies. They were housed in cages with wire-mesh floors, and offered a standard laboratory ration (Chadick's M164 Mouse Cubes) and water ad libitum. Lighting was strictly controlled: 12 hr on and 12 hr off.
In all experiments, and at all time intervals, there were two control animals (saline administration) and two treated ones, and all incubations were done and all tissues sampled in duplicate. '" Ilil \! : -Analysis by gas chromatograph (as described in text) of the digitonin precipitate prepared from the liver of a Phosfon-treated rat following injection of [1_ 14 Cjacetate. The dotted curve is the chromatograph trace of the tissue sample, whereas the solid curve is that of a mixture of cholesterol (C), lanosterol (L), and squalene (S). The histograms represent radioactivity found in the column effluent.
(b) Plant-growth Retardants Two retardants were used in these studies: Phosfon (tributyI2,4-dichlorobenzylphosphonium chloride), a gift from the Mobil Chemical Company, Ashland, Virginia, U.S.A.; and Amo 1618 (2-isopropyl-4-dimethylamino-5-methylphenyl-1-piperdine carboxylate methy1chloride), purchased from Calbiochem. They were dissolved in saline and given either by stomach tube or by intraperitoneal injection.
(c) Lipid Synthesis We measured the incorporation of the substrates, [1-14C]acetate and [2-14 C]mevalonate, into cholesterol and long-chain fatty acids in two systems, in vivo and in vitro, as well as the incorporation of [U-14C]glucose in vivo. These measurements were all made between 10 a.m. and 2 p.m., i.e. during the low phase of the diurnal ryhthm of cholesterol synthesis (Hickman et al. 1971) .
For synthesis in vivo, labelled precursor of high specific activity was) injected intraperitoneally at various times (indicated in each table) after retardant treatment, and after either 30 or 120 min the animals were decapitated and a variety of tissues was quickly collected or removed-blood, liver, kidneys, adrenals, intestine (the first few inches of duodenum), heart, lungs, and brain, in that order. Weighed amounts of each tissue, or a measured volume of plasma or serum, were placed in plastic centrifuge tubes, 1 ml of 30 % KOH added, and all heated overnight, with reflux, at 90°C. Before weighing the intestine its lumen was rinsed with cold saline, and any adhering adventitia were removed. Following saponification, 14C-Iabelled cholesterol (as the digitonin precipitate) and long-chain fatty acids were extracted and counted as described previously (Sabine et al. 1967) . Results were then expressed as counts min-1 mg-1 wet weight of tissue. The limitations of this technique as a measure of absolute synthesis are particularly relevant in these studies and will be discussed later. Total cholesterol was determined by the Liebermann-Burchard procedure (Abell et al. 1952) . Synthesis in vitro, by liver slices, was measured as described previously (Sabine et al. 1967) . Under our conditions the counting efficiency of the cholesterol preparation is approximately 90 % that of the fatty acids. We have tested the validity of our extraction and incubation methods in several experiments, conducted in conjunction both with the present studies and with those reported earlier (Paleg and Sabine 1971) . We have found that no radioactivity from any of our 14C-labelled substrates (acetate, mevalonate, or glucose), when added directly to saponifying tissue, appears in either the cholesterol or fatty acid fractions subsequently isolated. Furthermore, by thin-layer and gas-liquid chromatography, 85-90 % of the digitonin precipitate from both control and Phosfon-treated animals appears to be cholesterol. Figure 1 shows the results of a typical assay of the digitonin precipitate derived from an extract of the liver of a Phosfon-treated animal. The sterol digitonide was split with pyridine (60°C for 1 hr), the sterols were extracted and concentrated, and an aliquot injected into a Shimadzu GC-IC gas chromatograph (glass column, 1'86 m by 0·4 cm, packed with 2% SE-30 on Anachrom ABS support). Of this sample, 10 % was passed through the chromatograph detector and 90 % collected onto methanol-soaked glass wool and subsequently counted for radioactivity. The figure shows chromatograph traces for both the unknown sample and for a mixture of commercially obtained cholesterol, lanosterol, and squalene; the sample radioactivity values are superimposed.
III. RESULTS
(a) Mortality
The death rate in our experiments, following administration of the retardants by gavage and by intraperitoneal injection, is shown in Table 1 . Amo 1618 appears to be at least 100 times more lethal than Phosfon, when administered by injection. The manufacturer reports for Phosfon an acute oral LD50 for male albino rats of 178 mg/kg.
(b) Wean lings
In six separate experiments young male rats were treated with Phosfon and subsequently tested at various times for their ability to synthesize in vivo cholesterol and fatty acids from [1-14 C]acetate. For liver, the results we obtained for apparent lipid synthesis, as counts min-1 mg-1 wet weight of tissue, for control and treated animals, were as follows: cholesterol, 6·1 ±2·1 and 5·9 ±3·0; fatty acids, 32·6 ±5· 5 and 41·1 ±12 ·2, both statistically insignificant changes. Similarly for the other tissues sampled (intestine, brain, heart, lung, and kidney) the Phosfon treatment had no apparent effect. Also, we detected no effect of another retardant, Amo 1618, in two experiments. The dosages and routes employed were those shown in Table 1 . In vivo* (counts min-1 mg-1)
In vitro recovery of 14C (%)t
* Animals were killed and tissues sampled 2 hr after intraperitoneal injection of acetate Table 2 shows the results of our first two experiments on the effect of Phosfon intraperitoneally on lipid synthesis in vivo in adult rats. [1-14 C]Acetate was injected intraperitoneally either 2 or 12 hr after the retardant. The major, and unexpected, feature of these results was the striking increase in apparent synthesis of cholesterol by liver. At a dose of 7·0 mg/kg this increase was evident after 12 hr, but not after only 2 hr. At the higher dose rate (14·0 mg/kg), the increase was apparent even after 2 hr. There was a smaller increase in apparent cholesterol synthesis by the intestine and little or no change in apparent fatty acid synthesis by either tissue.
(c) Adult Rats
Although Phosfon caused as much as a 5· 6-fold increase in incorporation of [14C]acetate into cholesterol by liver in vivo, there was no consistent increase in the capacity of the liver to synthesize cholesterol in vitro. Amo 1618 (0 ·14 mgjkg, intraperitoneally) was also tested in the same experiments, but produced no effect either in vivo or in vitro. * These animals were offered food and water ad libitum after injection of Phosfon or saline.
All others were offered water only.
In the following experiment (Tables 3 and 4 ) Phosfon (14·0 mg/kg) was again injected intraperitoneally, and at different times subsequently the rats were tested Values (expressed in counts min-1 mg-1 of tissue) are means ± S.E. for tissues taken from the 10 control and 10 treated rats also reported in Table 3 Cholesterol Table 2 , and again indicated a large increase (c. fivefold) in apparent cholesterol synthesis in vivo in the liver (Table 3 ) and smaller increases (c. twofold) in the intestine, kidney, adrenal, heart, and lung, with no change in the brain (Table 4) . Phosfon caused smaller effects on the apparent synthesis of long-chain fatty acids in liver (i.e. a twofold increase) and produced no obvious effect on fatty acid synthesis in the other tissues tested. Table 3 also indicates that the promotion by Phosfon of apparent cholesterol synthesis was both rapid and prolonged, since the effect was the same whether [1-14 C]acetate was injected at the same time as Phosfon or up to 48 hr later. The increase in radioactivity in both cholesterol and fatty acids in the plasma probably reflected the increased incorporation by liver. There was no increase, however, in circulating levels of total cholesterol, nor any change in hepatic lipogenic capacity in vitro.
It was obvious at this stage that our original expectation, i.e. of finding either a decrease in sterol synthesis, in keeping with the in vitro results reported earlier (Paleg and Sabine 1971) , or perhaps no effect at all, was wrong. The clear stimulation of precursor incorporation into cholesterol in vivo following intraperitoneal injection ofPhosfon raised several important questions. Was Phosfon really influencing sterol synthesis, or was it affecting the further metabolism of cholesterol? If synthesis were being affected, did Phosfon act before or after mevalonic acid, an important stage in the physiological regulation of cholesterol synthesis? Could some general effect, such as an alteration in membrane permeability, be involved?
It seemed likely that a number of questions could be answered by assessing the Phosfon effect (at 14·0 mgjkg) when both acetate and mevalonate were used as precursors. These compounds were injected 12 hr after injection of Phosfon, and all animals were killed 30 min later. The results (Table 5) again demonstrated the large Phosfon-induced increase in apparent cholesterol synthesis from [1-14 C]acetate, especially in the liver, and a smaller but still considerable increase in apparent fatty acid synthesis. On the other hand, there was no effect at all of Phosfon on cholesterol or fatty acid synthesis from [2-14 C]mevalonate. As discussed in an earlier report (Paleg and Sabine 1971) , it seems probable that radioactivity found in the fatty acid fraction isolated following mevalonate administration represents terpenoid acids, by-products of the sterol biosynthesis pathway. The absence of an effect of Phosfon on mevalonate incorporation into cholesterol would seem to eliminate the possibility of any action of the retardant, direct or indirect, either on the metabolic pathway subsequent to mevalonate, or on the further metabolism of cholesterol. There was no stimulation of isotope incorporation in vitro from either [1-14C]acetate or [2-14 C]mevalonate.
At this time we measured also the effect ofPhosfon on tissue levels of cholesterol. The values obtained are given in Table 6 , and from these results it is clear that there was no effect. Thus it is unlikely that the action of Phosfon is on cholesterol pool size. We were interested to observe that in control animals the kidney accumulated relatively greater amounts of radioactivity in both cholesterol and fatty acids from [14C]mevalonate than from [14C]acetate. Some comparative calculations are shown in Table 7 . The differential incorporation of acetate and mevalonate into cholesterol in various tissues probably reflects differential permeability of the tissues to the two precursors. Mevalonate is apparently of relatively greater importance to the kidney than to other tissues, and the kidney was also the only tissue to show significant amounts of radioactivity in the non-digitonin-precipitable fraction isolated during the cholesterol determination. This special role of mevalonate metabolism in the kidney has also been observed recently by Siperstein (personal communication).
On the assumption that labelled glucose would generate intracellular labelled acetyl CoA, we compared the effect of Phosfon on the incorporation of [l_14C]acetate and [U-14C]glucose into cholesterol and fatty acids. Again the precursors were injected 12 hr after the retardant, and the animals were killed 30 min later. The results of two separate experiments, with varying amounts of [U-14C]glucose, are included in Table 5 , and show that there was no effect of the retardant on the incorporation of glucose (and thus presumably of acetyl CoA) into cholesterol.
As yet we have not measured any direct effect of Phosfon on other aspects of acetate metabolism, but we have found that plasma levels of acetate were unaffected; 113 nmoles/ml in normal and 116 nmoles/ml in Phosfon-treated rats. 
IV. DISCUSSION
On the basis of our experiments with cell-free preparations and with tissue slices (Paleg and Seamark 1968; Paleg I 970a, 1970b; Paleg and Sabine 1971) , we expected that both Phosfon and Amo 1618 might cause detectable decreases in sterol synthesis when injected into normal rats. Both retardants, in common with other sterol synthesis inhibitors (Holmes and Di Tullio 1962) , appear to act at specific points in the biosynthetic sequence leading to cholesterol (Paleg 1970b) , and Amo 1618 has been shown (Paleg, unpublished data) to cause the accumulation of squalene-2,3-epoxide, thus indicating an inhibition of the cyclization step.
So far we are unable to explain the apparent failure of the retardants to act in vivo as they do in vitro. Phosfon, however, did produce a significant effect on lipid metabolism in vivo but, since this response was not elicited by Amo 1618, it seems unlikely that the effect can be considered a general one of plant-growth retardants, although the distribution and accumulation of these compounds in various tissues following injection has yet to be determined.
The effect of Phosfon on lipid metabolism was analysed statistically (Student's t-test), by comparing the values obtained for the incorporation of [P4C]acetate into cholesterol and fatty acids (as counts min-I mg-I tissue or counts min-I ml-I ) in the 10 control and 10 treated animals shown in Tables 3 and 4 . Stimulation of incorporation into cholesterol was significant for liver and intestine (P> 0·001), kidney and lung (P>O·Ol), and plasma (P>O·S). Incorporation into fatty acids was significant only for the liver (P>O·OOl).
It is of course clear that the rate of synthesis of a product by an intact tissue cannot be accurately assessed simply by determining the incorporation of radioactive precursors into that product. Nonetheless, the experiments reported in this work leave little doubt that Phosfon causes a significant stimulation of the incorporation of exogenous acetate into cholesterol in the liver and several other tissues. The lack of a similar effect on mevalonate and glucose incorporation militates against any stimulation of absolute cholesterol synthesis or any alteration of sterol metabolism subsequent to cholesterol.
Several possibilities still exist for explaining the Phosfon effect. The growth retardant may be altering the permeability of liver and intestinal membranes to acetate (in ways that do not affect the passage of mevalonate or glucose); the esterification of acetate to yield acetyl CoA may be stimulated; the pool size of acetate (or acetyl CoA) may be altered; and lastly, since compounds similar in action to Phosfon have been shown to inhibit acetylcholinesterase (Friess and McCarville 1954) and pseudo-cholinesterase (Newhall 1969 ) activity, there is the possibility that a general disruption of the acetate economy of the animal results from an inhibition of one or both of these enzymes.
One further point arises from this work. In those tissues in which there was an apparent stimulation of acetate incorporation there was always a greater effect on cholesterol than on fatty acid formation. Assuming there is no direct effect of Phosfon on either pathway, it would appear, therefore, that either there are separate acetate pools for the two pathways, or that the two biosynthetic routes respond differently to an increase in the supply of the common precursor.
Clearly, the results presented here do not permit more than speculation on the way Phosfon influences cholesterol biosynthesis in vivo in rat tissues. With the exception of Actinomycin D (De Matteis 1968), we know of no other compound that produces the marked increases in apparent cholesterol synthesis in vivo induced by Phosfon, and it is most unlikely that the effects of Actinomycin D are comparable with those of the retardant. It does seem likely, however, that further investigation of the Phosfon effect will help clarify our understanding of the mechanisms controlling mammalian lipid metabolism. It also seems essential that further information be gained about the mechanism of action of plant-growth retardants in mammalian systems before the compounds are introduced further into large-scale agricultural use.
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